尼洛替尼联合PD-L1阻断逆转CD4+ T细胞功能障碍并预防急性B细胞白血病复发
研究利用Ph+ B-ALL小鼠模型及人类骨髓活检样本,探讨CD4+ T细胞耗竭的本质及酪氨酸激酶抑制剂尼洛替尼联合抗PD-L1治疗的临床前潜力。单细胞RNA测序显示B-ALL诱导出兼具细胞毒与辅助功能的独特CD4+ T细胞亚群;尼洛替尼联合抗PD-L1显著改善白血病小鼠长期生存,且该获益依赖于CD4+ T细胞。
要点
- B-ALL诱导出兼具细胞毒与辅助功能的独特CD4+ T细胞亚群。
- 尼洛替尼联合抗PD-L1显著改善白血病小鼠长期生存。
- 抗PD-L1治疗促进白血病特异性CD4+ T细胞克隆扩增并降低耗竭标志物表达。
核心结论
- 尼洛替尼联合抗PD-L1可逆转CD4+ T细胞功能障碍并预防急性B细胞白血病复发,支持在临床试验中使用PD1/PD-L1检查点阻断。
研究设计与样本
- 研究使用Ph+ B-ALL小鼠模型及人类骨髓活检样本,评估CD4+ T细胞耗竭的基本性质及抗PD-L1联合靶向BCR-ABL的酪氨酸激酶抑制剂的临床前治疗潜力。
主要发现
- 单细胞RNA测序分析显示B-ALL诱导出一群兼具细胞毒与辅助功能的独特CD4+ T细胞。
- 尼洛替尼联合抗PD-L1显著改善白血病小鼠的长期生存。
- 治疗前清除CD4+ T细胞完全消除了生存获益,提示CD4+ T细胞是保护性抗白血病免疫反应的关键驱动因素。
- 抗PD-L1治疗导致具有上述辅助/细胞毒表型的白血病特异性CD4+ T细胞克隆扩增,并降低耗竭标志物的表达。
临床怎么用
- 作者认为这些发现支持在临床试验中使用PD1/PD-L1检查点阻断,并强调CD4+ T细胞功能障碍在限制内源性抗白血病反应中的重要性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with acute lymphoblastic leukemia have experienced significantly improved outcomes due to the advent of chimeric antigen receptor (CAR) T cells and bispecific T-cell engagers, although a proportion of patients still relapse despite these advances. T-cell exhaustion has been recently suggested to be an important driver of relapse in these patients. Indeed, phenotypic exhaustion of CD4+ T cells is predictive of relapse and poor overall survival in B-cell acute lymphoblastic leukemia (B-ALL). Thus, therapies that counter T-cell exhaustion, such as immune checkpoint blockade, may improve leukemia immunosurveillance and prevent relapse. Here, we used a murine model of Ph+ B-ALL as well as human bone marrow biopsy samples to assess the fundamental nature of CD4+ T-cell exhaustion and the preclinical therapeutic potential for combining anti-PD-L1 based checkpoint blockade with tyrosine kinase inhibitors targeting the BCR-ABL oncoprotein. Single-cell RNA-sequence analysis revealed that B-ALL induces a unique subset of CD4+ T cells with both cytotoxic and helper functions. Combination treatment with the tyrosine kinase inhibitor nilotinib and anti-PD-L1 dramatically improves long-term survival of leukemic mice. Depletion of CD4+ T cells prior to therapy completely abrogates the survival benefit, implicating CD4+ T cells as key drivers of the protective anti-leukemia immune response. Indeed, treatment with anti-PD-L1 leads to clonal expansion of leukemia-specific CD4+ T cells with the aforementioned helper/cytotoxic phenotype as well as reduced expression of exhaustion markers. These findings support efforts to use PD1/PD-L1 checkpoint blockade in clinical trials and highlight the importance of CD4+ T-cell dysfunction in limiting the endogenous anti-leukemia response.
引用
- Tracy SI, Venkatesh H, Hekim C, et al. Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemia. Blood. 2022. PMID: 35275990. doi:10.1182/blood.2021015341
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。